ent-Rivaroxaban(CAS: 865479-71-6)

Ent-Rivaroxaban (CAS: 865479-71-6) is subject to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) and REACH regulations in the European Union. It is also regulated by the FDA and EPA in the United States. Manufacturers and distributors are required to provide Material Safety Data Sheets (MSDS) and comply with local and international regulations regarding hazardous substances.

Alternative reagents to ent-Rivaroxaban (CAS: 865479-71-6) include other direct thrombin inhibitors such as argatroban and dabigatran. In synthesis, chemists often explore isomers and analogs like ent-N-methyl rivaroxaban, which can serve as viable alternatives due to similar pharmacological properties.

The market for ent-Rivaroxaban (CAS: 865479-71-6) continues to grow due to its efficacy in treating deep vein thrombosis and pulmonary embolism. Research trends focus on its potential in cardiology and hematology, as well as its role in cardiovascular risk reduction. Price trends indicate steady demand with slight fluctuations driven by clinical trial outcomes and new therapeutic indications.

Waste containing ent-Rivaroxaban (CAS: 865479-71-6) should be collected in appropriate containers labeled with the chemical name and CAS number. It should be kept in a secure area to prevent environmental contamination. For disposal, engage professional hazardous waste management services to ensure compliance with local and international regulations. Proper incineration or landfilling methods should be utilized to minimize environmental impact.